Long-term Durable Humoral Immune Response to Heterologous Antigenic Exposure Post six months by Natural SARS-CoV-2 Infection and Vaccination

Methods

The participants were sampled cross-sectionally from an ongoing DBT COVID-19 Research Consortium cohort between November 2021 and January 2022 (Appendix). We included five groups of individuals who had completed six months after complete vaccination: (i) vaccination with ChAdOx1 nCoV-19 and aged 18-59 years, (ii) vaccination with ChAdOx1 nCoV-19 and aged ≥60 years (iii) vaccination with BBV152 and aged 18-59 years (iv) vaccination with BBV152 and aged ≥60 years (v) vaccination with either vaccine plus prior SARS-CoV-2 infection referred as those having hybrid immunity. A group of unvaccinated individuals was also included for comparison. Written informed consent was obtained from the study participants. Institute ethics committees approved the study.

The study participants were interviewed for details on SARS-CoV-2 vaccination including the type, number of doses, and date of vaccination, profession, comorbidities and prior SARS-CoV-2 infection. The dates of vaccination were verified by the certificate issued by Government of India. Five percent of interviews were monitored for quality control.

Anti-RBD IgG concentrations in the plasma samples were determined by enzyme-linked immunosorbent assay (ELISA) as described earlier with minor modifications and are reported as BAU/mL.⁵ In addition, anti-nucleocapsid antibodies were detected using a qualitative ELISA.

We estimated a sample size of at least 296 participants for each group to detect a decline of anti-IgG RBD by 30% after 6 months of vaccination with 80% power and at 5% significance after adjusting for multiple comparisons. The baseline characteristics are given as median (interquartile range) or number (percentage) as appropriate. The differences in ELISA titers between different groups were compared using unpaired Student’s t-test after log2 transformation. Categorical parameters were compared by chi-square test. All statistical analysis was done using R 4.1.1. A p-value of <0.05 was considered statistically significant.

Results

We included 2003 vaccinated (1005 ChAdOx1 nCoV-19 and 998 BBV152) and 94 unvaccinated individuals(Figure S1). The median duration after the second dose of vaccine to inclusion was 246 days (IQR: 222, 283). Prior SARS-CoV-2 infection was reported by 21% (421 of 2003) vaccinated and 87% (82 of 94) unvaccinated individuals. The characteristics of participants are provided in Table 1.

The anti-RBD IgG antibodies were undetectable (cut-off of 24 BAU/ml) in 15% (300 of 2003) of the vaccinated participants. The median serum anti-RBD IgG antibody titer among the ELISA positive participants was 163 (IQR 73, 403) BAU/ml. In the hybrid immunity group, 98% tested positive for anti-RBD IgG compared to 81% of only vaccinated participants (p <0.001). The anti-RBD IgG titer in those with hybrid immunity [295 (IQR 128, 687)] BAU/mL was significantly higher than only vaccinated participants [139 (IQR 62, 326); p <0.001]. The median anti-RBD IgG titers were higher in the ChAdOx1 nCoV-19 groups than in the BBV152 groups. In the ChAdOx1 nCoV-19 group, the median anti-RBD IgG titers were higher in ≥60 years participants [242 (IQR 106, 583) BAU/ml] compared to those <60 years [150 (IQR 71, 314) BAU/ml; p <0.001] (Table 2, Figure 1).

• Download figure
• Open in new tab

Figure 1:

Comparison of anti-RBD IgG titer (BAU/mL) in different participant groups

Anti-nucleocapsid antibodies, which may be induced by natural infection or the whole inactivated virus BBV152 vaccine, were detected in one-fourth (505 out of 2003) of the vaccinated population. The prevalence of anti-N antibodies was 36% (152 of 421) in the hybrid immunity group and 28% (237 of 842) in the uninfected BBV152 vaccinated individuals. The prevalence in the ChAdOx1 nCoV-19 group was 9.5% (37 of 388) in those <60 years and 22% (79 of 352) in those aged 60 and above. The median anti-RBD IgG titer in the anti-nucleocapsid positive participants [326 (IQR 132, 739) BAU/ml] was significantly higher than those without anti-nucleocapsid antibodies [131 (IQR 58, 288) BAU/ml; p <0.001] (Table S1).

Discussion

In summary, we have shown the durability of IgG anti-RBD antibodies in 85% of participants beyond a median of 8 months after complete vaccination. The antibody concentrations were significantly higher in those with hybrid immunity.

Humoral immune responses to mRNA vaccines are known to wane over a period of time, particularly after 5 months, more so in individuals older than 60 years of age.^6,7 But these may not be generalizable to other vaccine types and in different geographic regions in the context of immunity provided by natural infection. In the present study, we found higher positivity and higher levels of antibodies among those with hybrid immunity. In the vaccinated group, it is probable that many participants had prior asymptomatic infection consistent with a high seroprevalence of natural infection in the population.^8,9 We found 15% ChAdOx1-nCoV-19 only participants positive for anti-nucleocapsid antibody suggesting previous infection. However, in the vaccination plus infection group, nearly two-thirds of participants were negative for anti-nucleocapsid antibody possibly suggesting faster waning of anti-nucleocapsid than anti-RBD antibodies.¹⁰ If we extrapolate this finding to vaccine alone groups, 45% ChAdOxnCoV-19 group might have had asymptomatic natural infection and a similar percentage in the BBV-152 vaccine given the almost similar vaccine effectiveness of these 2 vaccines.^11,12

This inference is important because most countries have been affected by a minimum of three waves of different SARS-CoV-2 VoCs, most recent being omicron, infecting a large proportion of population. Such a natural infection should be equivalent to at least another dose of vaccine, reinforcing the protection provided by vaccination alone. It is likely that other modes of protection such as cellular responses provided by natural infection are better than those induced by vaccines. Clinically, naturally infected people have shown to be better protected than vaccination alone.¹³ Current data suggest that vaccination plus natural infection provides even better protection.^14,15 Therefore, recommendation for boosters should take into account past infections in the population.

The strengths of our study include inclusion of inactivated vaccine about which sparse data are available, adequate sample size, inclusion of different age groups and profiling anti-nucleocapsid antibody positivity for unidentified past infections. Our study has a few limitations, inability to unequivocally identify individuals with prior infection, and a small sample size of unvaccinated group, a reflection of >90% of eligible population having been vaccinated in India as in many other countries.

Our data may guide policy for a booster dose. Considering the wide seropositivity rates due to natural infection, the priority for a booster should be for vulnerable and high-risk groups.

Conflict of interest

We declare that we have no conflicts of interest.

Data sharing statement

The deidentified dataset and related codes for analysis may be available to researchers upon request addressed to the corresponding author after publication after the approval of the Department of Biotechnology, Government of India.

Contributors

PKG conceptualized and designed the overall study. SB, RT and NW designed the cohort study; DM, RT, SS, MG, PK, SJ, SG, AD, AP, TD, RG, RK, PS, SK, SKp, NS, SD and JB enrolled the participants, collected the clinical information and pre-processed the biospecimens; SC, FM, SJD and GB developed and performed the ELISA for antibody titres; RT, DM, A and GB managed and analyzed the clinical and laboratory data; PKG, SB, GB, RT reviewed and interpreted the data, and wrote the manuscript; all authors reviewed and approved the final manuscript.

None of the authors were paid by any pharmaceutical company or any other agency to write this article. All authors had full access to the full data in the study and accept responsibility to submit for publication.